What is the typical dose of ergotamine for migraine treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ergotamine Dosing for Migraine Treatment

For acute migraine treatment, start with 1-2 mg of ergotamine orally at the first sign of headache, repeat 1 mg every hour if needed, with a maximum of 3 doses (6 mg) per 24 hours and no more than 10 mg per week. 1, 2

Oral Ergotamine Dosing

  • Initial dose: 1-2 mg at headache onset 1, 2
  • Repeat dosing: 1 mg every hour as needed 1, 2
  • Maximum per attack: 3 doses (3-6 mg total) 1, 2
  • Maximum per 24 hours: 6 mg 1
  • Maximum per week: 10 mg regardless of route 1, 3

The FDA label for Ergomar® specifies no more than 2 tablets per single migraine attack and no more than 5 tablets during any 7-day period. 4

Ergotamine + Caffeine Combination (Cafergot)

  • Initial dose: 2 tablets (each containing 1 mg ergotamine + 100 mg caffeine) at onset 1
  • Repeat dosing: 1 tablet every 30 minutes 1
  • Maximum per attack: 6 tablets 1

Rectal Suppository Dosing

  • Initial dose: 1 mg suppository at onset 1
  • Repeat dosing: May repeat in 1 hour if needed 1
  • Maximum per day: 2-3 suppositories 1, 2
  • Maximum per month: 12 suppositories 2

Rectal administration is the most effective form of ergotamine, particularly for patients with severe, rapid-onset migraine accompanied by nausea and vomiting, achieving 73% headache relief compared to 63% with rectal sumatriptan. 5, 6

Critical Timing and Frequency Restrictions

Administer at the earliest sign of migraine—delayed dosing significantly reduces efficacy. 1, 7 Ergotamine should be taken at the first sign of headache pain, as effectiveness depends critically on early administration. 7, 8

Limit use to 2 days or fewer per week to prevent medication-overuse headache. 1, 7 This restriction is essential because ergotamine has a substantially elevated risk of causing rebound headaches compared to other acute treatments. 7

Route Selection Based on Clinical Presentation

  • Oral tablets: Best for slowly evolving migraine without early nausea/vomiting 5
  • Rectal suppositories: Preferred for severe, rapid-onset migraine with nausea/vomiting 5
  • Inhalation: Alternative for patients who cannot tolerate oral or rectal routes 9

Absolute Contraindications to Dosing

Do not administer ergotamine in the following situations:

  • Concurrent triptan use—must wait 24 hours between ergotamine and triptans 1, 7
  • Pregnancy and lactation due to oxytocic effects 2, 7, 4
  • Cardiovascular disease including coronary artery disease, uncontrolled hypertension, peripheral vascular disease 1, 2, 7
  • Concurrent use with CYP3A4 inhibitors (macrolide antibiotics, protease inhibitors) due to increased vasospasm risk 1, 4
  • Concurrent beta blockers or MAOIs 2, 4

Current Clinical Positioning

Ergotamine is now considered a third-line option after failure of NSAIDs and triptans. 7 The American College of Physicians guidelines establish that ergotamine should only be considered after patients fail combination therapy of a triptan plus NSAID or acetaminophen, due to its higher risk of medication-overuse headache and inferior tolerability. 7

Triptans are generally preferred over ergotamine due to higher efficacy, fewer adverse effects, more predictable absorption, and lower risk of medication-overuse headache. 1, 8

Specific Patient Populations Where Ergotamine May Be Appropriate

  • Patients with infrequent migraines who can reliably limit use 7, 8
  • Patients with long-duration attacks where sustained vasoconstriction may be beneficial 7, 8
  • Patients who have failed or cannot tolerate triptans 7, 8

Warning Signs of Ergotism

Patients must report immediately: numbness or tingling in fingers and toes, muscle pain in arms and legs, weakness in legs, chest pain, or coldness of extremities. 4 These signs indicate ergotism from vasoconstriction and require immediate discontinuation. 4

References

Guideline

Ergotamine Dosage and Administration for Migraine Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Ergotamine Medications: Clinical Use and Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Ergotamine and dihydroergotamine: a review.

Current pain and headache reports, 2003

Guideline

Ergotamine Use in Migraine Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of the acute migraine attack--current status.

Cephalalgia : an international journal of headache, 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.